BACKGROUND: Osteoporosis is a prevalent condition that may lead to increased risks for
bone fracture and other morbidities and increased health care costs. Treatment modalities …

Importance of the field: Osteoporosis is a common skeletal disease that is associated with an
imbalance in bone remodeling. Denosumab is an investigational fully human monoclonal …

To summarize promising areas of investigation in osteoporosis and to stimulate further
research in this area, as discussed in a recent international conference. Over the recent …

Postmenopausal osteoporosis is a major concern to public health. Fractures are the major
clinical consequence of osteoporosis and are associated with substantial mor bidity …

Odanacatib, a selective cathepsin K inhibitor, decreases bone resorption, whereas
osteoclast number increases and bone formation is maintained, perhaps even increased on …

Highlights•'Anti-resorptive'drugs inhibit osteoclast differentiation or function by diverse
mechanisms.•Bisphosphonates are still the major drugs used for osteoporosis and skeletal …

Being a connective tissue, bone can increase or decrease its mass through the process of
remodeling. Using a discovery in the mid-1980s—that tumor necrosis factor (TNF) could …

Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of
nuclear factor-κB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on …

Introduction: Osteoporosis is a chronic, skeletal disorder characterized by compromised
bone strength and increased fracture risk; it affects 50% of women and 20% of men. In the …

Introduction: Osteoporosis is the most widespread skeletal disease requiring innovative
therapeutic strategies for its management. The understanding of receptor activator of nuclear …